DH Latest NewsDH NEWSLatest NewsNEWSInternational

Trial production of an mRNA vaccine begins in China

China’s CanSino Biologics Inc has entered ‘test production phase’ for its COVID-19 mRNA booster vaccine, the company said in a post on its social media account late on Thursday.

 

The vaccine, known as CS-2034, targets new Omicron variants of the virus, which are responsible for the vast majority of infections that have swept across China since the country began dismantling strict COVID curbs last month.

 

Until now, China has relied on nine domestically developed COVID vaccines that have been approved for use, including inactivated vaccines, but none of them have been adapted to target the highly transmissible Omicron variant and its offshoots, which are currently in circulation.

 

The CanSino booster vaccine is one of China’s first home-grown potential vaccines, based on mRNA technology similar to that used in Pfizer-BioNTech and Moderna vaccines produced internationally.

shortlink

Post Your Comments


Back to top button